Stuttgart - Delayed Quote • EUR Bayer AG (BAYN.SG) Follow Compare 21.34 +0.49 +(2.33%) As of 4:02:11 PM GMT+1. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Agtech Seedlings: CH4 Global to expand methane-reducing cattle feed with Mitsubishi Also in this week’s farm technology news: Deere & Co. will partner with six agtech startups in 2025, and Google makes two biochar carbon credit deals. Here’s Why Bayer Aktiengesellschaft (BAYRY) Declined in Q4 Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. For the quarter ended December 31, 2024, the fund returned -8.48% compared to the MSCI World ex USA Index’s -7.43% return. Since its inception, the fund returned 8.19% compared to a […] Jury orders Bayer to pay $100 million over PCBs in Washington school (Reuters) -A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals known as PCBs at a Seattle-area school, but found the company was not liable for injuries alleged by 11 others. The verdict, which follows a two-month trial, is the latest in a string of trials against the chemical company over the alleged contamination at the Sky Valley Education Center in Monroe, Washington. More than 200 students, employees and parents have said they developed cancer, thyroid conditions, neurological injuries and other health problems from polychlorinated biphenyls, or PCBs, leaking from the school's light fixtures. Agtech seedlings: Bayer, European refinery to scale US biofuel production Also in this week's farm technology news: Inari raised $144 million to bring gene-edited seeds to market and an Israel-based startup looks to develop its computer vision technology for horticulture. Bayer Secures End of Roundup Weedkiller Litigation in Australia The German pharmaceutical and agricultural conglomerate said the Federal Court of Australia closed the last pending case in the country over whether its Roundup weedkiller causes cancer. Bayer: Federal Court Brings an End to Roundup™ Litigation in Australia LEVERKUSEN, Germany, January 03, 2025--The Federal Court of Australia brought an end to the last Roundup™ case in Australia, closing all pending injury litigation there. The Court granted the plaintiffs’ request to discontinue the Fenton class action against Monsanto involving allegations related to Roundup™. This action follows the company’s earlier victory in the McNickle case in the same court. A year after Bayer got rid of bosses and asked staff to self-organize, its CEO says attrition has fallen Bayer told workers to self-organize last year as part of a plan to save €2 billion in costs by 2026. FDA Accepts Cytokinetics' Application for Cardiovascular Drug CYTK's NDA is seeking approval for the lead pipeline candidate, aficamten, which the FDA accepted and assigned a target action date of Sept. 26, 2025. FDA Accepts Bayer's Application for Label Expansion of Nubeqa Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA. Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization of aficamten in Japan. Bayer acquires rights to Cytokinetics' heart drug in Japan Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular business with smaller deals. Cytokinetics will receive 50 million euros ($53 million) upfront, plus up to 90 million euros contingent on certain development achievements, Bayer said in a statement. Cytokinetics also stands to receive up to 490 million euros from Bayer, depending on certain sales milestones. Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback AZN and BAYRY announce Q3 results. ABBV's studies on schizophrenia candidate, emraclidine, fail to meet goal. Agtech seedlings: Bayer gets into the AI business with Microsoft Also in this week's farm technology news: Nutella maker Ferrero invests in hazelnut research, and digital crop monitoring platform FarmQA acquires competitor Farm Dog. Bayer Third Quarter 2024 Earnings: Misses Expectations Bayer ( ETR:BAYN ) Third Quarter 2024 Results Key Financial Results Revenue: €9.97b (down 3.6% from 3Q 2023). Net loss... Bayer AG (BAYRY) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges Bayer AG (BAYRY) reports strong performance in Pharmaceuticals and Consumer Health, while facing headwinds in Crop Science and regulatory challenges. Bayer urges investor patience as weak agricultural market drags earnings The chemical giant cut its financial outlook as it faces slowing crop protection sales and regulatory uncertainty around glyphosate and dicamba herbicides. Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales BAYRY's third-quarter earnings get affected due to impairment losses at the Crop Science division. Sales gain from the Pharmaceutical business's strong performance. Stocks to Watch Tuesday: Tesla, Honeywell, Home Depot, Tyson Foods ↗️ Shopify (CA:SHOP, SHOP): The online-retail services company reported better-than-expected quarterly revenue and said growth could be even higher in the key fourth quarter. U.S.-listed shares rocketed about 25%. Bayer Stock Slumps on Outlook Cut Bayer shares are sinking in German trading after the pharmaceuticals and crop science conglomerate reduced its full-year earnings target amid a tough agricultural market. Trending tickers: Coinbase, Tesla, AstraZeneca, Metro Bank and SoftBank The latest investor updates on stocks that are trending on Tuesday. Performance Overview Trailing total returns as of 1/27/2025, which may include dividends or other distributions. Benchmark is DAX P Return BAYN.SG DAX P YTD +11.47% +7.09% 1-Year -32.98% +25.70% 3-Year -54.41% +37.91%